Oncolytic viruses, viral vectors for gene therapy and viral-vectored prophylactic vaccines, are new, innovative, and already successful approaches for the treatment of severe diseases. The production of these viruses requires extensive experience and specially-designed GMP clean rooms. Vibalogics offers both.
HistologiX appoints new Managing Director
AppointmentsBarbara McManus as the new managing director of Nottingham-based Contract Research Organisation (CRO) HistologiX.
The end of partnering events as we know them
Latest NewsAn ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering event’s scheduled one-on-one meetings online is neither imaginative nor does it meet the requirements of flexibility and effectiveness. The format presented here sounds the bell for a new era of pharma partnering.
BioNTech and Fosun Pharma kick off Chinese COVID-19 trials
Latest NewsBioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec partners with Secarna to develop LNA drugs
Latest NewsEvotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
Rapid test for pandemics
Latest NewsRapid tests have received a lot of attention during the Coronavirus pandemic, but as the number of tests available has increased, so has the confusion around the different types and what they can deliver. What if there were laboratory quality tests that could produce a result in just a few minutes?
EC secures 300 million doses of COVID-19 vaccine
Latest NewsThe European Commission has reserved 300 million doses from Sanofi SA’/GSK plc’s adjuvanted recombinant COVID-19 vaccine.
Antiviral drugs for pandemic preparedness
Latest NewsViral pandemics are not a once-in-a-lifetime event but a constant threat looming over our heads. While the fight against SARS-CoV-2 is currently a top priority, we should not lose sight of what might come next. Broad-spectrum antiviral drugs like Atriva’s ATR-002, currently in Phase II clinical development for treating COVID-19, could be an effective measure in the fight against the current pandemic and future viral outbreaks.
Roche’s IL-6 receptor blocker fails in Phase III
Latest NewsRoche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Enthera Pharmaceuticals Srl raises €28m in Series A financing
Latest NewsItalian start-up Enthera Pharmaceuticals has raised €28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Vital expertise in oncolytic virus production
Latest NewsOncolytic viruses, viral vectors for gene therapy and viral-vectored prophylactic vaccines, are new, innovative, and already successful approaches for the treatment of severe diseases. The production of these viruses requires extensive experience and specially-designed GMP clean rooms. Vibalogics offers both.